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Abstract
While liver resection for colorectal metastases has shown promising long-term survival, data for metastasectomy in sarcoma
and leiomyosarcoma patients have not yielded the same optimism. Due to the rarity of the tumour entity it has always been
difficult to provide significant data. Advances in tumour classification suggest that most of the metastases formerly classified
to be of sarcomatoid and especially leiomyosarcomatoid origin are actually metastases of GISTs (gastro-intestinal stromal
tumours). Neoadjuvant/adjuvant imatinib therapy might improve overall survival and enable surgeons to provide resections
in previously unresectable patients. Only R0 resection has been proven to prolong survival so far, with a long disease-free
interval as the only independent predictor of outcome.
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Introduction
Liver resection for metastatic disease has become one
of the main pillars of interdisciplinary oncologic
therapy in cancer patients. Through major advances
in resection techniques and perioperative manage-
ment even extended liver resection is now viewed as a
safe procedure if performed at dedicated centres, with
a mortality of B/5% [1]. Good results with promising
5-year survival rates have been well documented for
metastatic colorectal cancer in recent years [2,3].
Data for liver resection for metastatic sarcoma have
not yielded the same optimistic standpoint so far
/ still it has been viewed as the best treatment option
if an R0 resection is possible [4/6].
As the understanding of the diversity in tumour
biology of sarcomas has dramatically changed over the
past 5 years with the discovery of KIT tyrosine kinase
and the definition of GISTs (gastro-intestinal stromal
tumours) as an entity [7,8], one is led to rethink the
available data in terms of realizing that most of the
sarcomas and especially leiomyosarcomas described
until recently are actually GISTs. Therefore, account-
ing for today’s knowledge, indications for resection
and patient survival might differ substantially from
previous data if auxiliary treatment options like
imatinib (STI571, Gleevac) are considered.
Pathology
The progress achieved in classifying primary and
secondary sarcomas of the liver derives largely from
the application of new methods in immunohistochem-
istry (antibodies, working on formalin-fixed and
paraffin-embedded tissue) and molecular pathology,
revealing specific genetic alterations. The vast major-
ity of primary sarcomas of the liver are of angiogenic
origin, i.e. angiosarcoma or epithelioid haemangioen-
dothelioma.
Other primary sarcomas are very rare and suspected
to represent metastasis of known or unknown origin,
for instance in cases of late metastasis of low grade
sarcomas [9].
GISTs and their metastases can be determined by
expression of CD 117/c-kit or PDGF-alpha through
immunohistochemistry [10].
An association between KIT exon 9 mutations and
an intestinal origin of GISTs and between PDGFRA
mutations and gastric origin of the tumours has been
shown. Mutational status (in contrast to only ampli-
fication) was correlated with high risk/malignant
GIST. Furthermore, the morphological phenotype is
correlated with specific mutations [11]. A striking
difference in gene expression between stomach and
small bowel GISTs has already been shown by gene
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array examination [12], explaining their variable
behaviour and response to therapy.
An up to date classification of secondary liver
sarcomas should include the examination of the
expression status for c-Kit/Cd-117 and PDGF-alpha
using immunohistochemistry. As not only immuno-
histochemistry but also extraction of suitable DNA
from paraffin-embedded archival tissue is practicable
[13], a retrospective reclassification by immunohisto-
chemistry and molecular pathology of already
published larger series of secondary malignant
mesenchymal tumours should be achieved to obtain
the real rate of GISTs in hepatic metastasis and a
better correlation with clinical data, especially survival
rates.
Liver resection
The available data for these tumour entities
are limited. Considering the new classification for
sarcomas it is important to keep in mind that nearly all
available data are derived from collections of patients
that were not identified by applying those new
classifications.
Additionally, most data concern calculated
survival rates for patient collections including all
kinds of non-colorectal, non-neuroendocrine
(NCNNE) tumours / therefore it is difficult to extract
data for sarcomas, especially if the new definitions are
applied.
Table I provides an overview of studies for NCNNE
tumours including sarcoma. Table II shows the data
from series that focused on sarcomas but did not
differentiate GISTs as an entity. The tables include
the estimated amount of GIST cases as extracted
from the data where possible.
Liver resection itself is considered a safe procedure
nowadays [1] and it is still the only treatment available
with the possible chance of a cure for metastatic
disease. Therefore aggressive attempts at R0 resection
are justified [6,14,15]. New strategies like portal
embolization aimed at inducing hypertrophy of
tumour-free parenchyma allow even more extensive
resections.
Discussion
Liver resection for metastatic disease of colorectal
cancer has been widely established as a safe procedure
and promising curative approach. Even second and
third resections after tumour recurrence have shown
acceptable results with an overall 5-year survival of up
to 40% [1/3].
Unfortunately the data for metastasis of sarcoma
and leiomyosarcoma are not that clear. Only one
larger series concerning hepatic metastases from
leiomyosarcoma [6] and one for metastatic sarcoma
[15] are available at present, while other publications
describe only few cases [8,14,16/18]. As the tumour
entity is rather rare the described cases are usually
published as part of series of NCNNE tumours
[4,5,19/21].
Considering the rather recent advances in patholo-
gic definitions of sarcomas it could be well argued
that the published series are not up to date, as the
new classification and diagnostic tools concerning
sarcomas were not available at the time of publication
[7,22,23]. DeMatteo found that 40% of all patients
treated for metastatic sarcoma actually had GISTs
[15]. Nevertheless, the results of all published series
have established an improved survival after R0 resec-
tion of roughly 30 months and a possible 5-year
survival rate of 20%, slightly favouring metastases of
sarcomas over leiomyosarcomas compared with non-
operative treatment. Without treatment the median
survival of patients is B/14 months, while chemother-
apy and chemoembolization usually provide poor
response rates and a median duration of regression
for 12 months [5].
The key to success is patient selection. The poor
results for patients with R1/R2 resections, especially
in face of extrahepatic tumour masses, are still better
than the results accomplished with chemotherapy or
chemoembolization but nevertheless are poor, with a
median survival of 20 months. This justifies an
aggressive attempt at R0 resection considering ex-
tended hepatectomies and even extracorporeal liver
resections [6,14]. Patients have to be evaluated care-
fully before any surgical attempt is made, focusing on
the existence of extrahepatic tumour and possible liver














Ercolani et al. 2004 Bologna, Italy 83 10 10 75% 63% 36%
Karavias et al. 2002 Patras, Greece 18 4 4 Not recorded 3 alive after 2 years 1 alive after 4 years
Kalil et al. 1999 Porto Alegre, Brazil 5 5 4 100% 75% 0%
Harrison et al. 1997 New York, USA 96 27 14 Not recorded Not recorded 26%
GIST, gastrointestinal stromal tumour; LMSC, leiomyosarcoma; NCNNE, non-colorectal, non-neuroendocrine; SC, sarcoma.
*Sarcoma and leiomyosarcoma cases account for a small number of tumours in these studies. GISTs have not been identified separately.
The likely amount of GISTs in the series are mentioned in the ‘supposedly GISTs’ section of the table. The survival rates display results for
the concerned subgroups.
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resection. Induction of hypertrophy through portal
vein embolization might be feasible in cases where a
resection would be otherwise limited due to a small
liver remnant [24]. A second liver resection for
tumour recurrence suggests benefits in terms of
survival [6], but long-term survival in this group of
patients has not been reported yet. It is reasonable to
speculate that most of the lesions formerly called
sarcomas and leiomyosarcomas in previous studies
would be classified as GISTs nowadays. Considering
the rather promising results of medical treatment with
imatinib it seems reasonable to think about neoadju-
vant and adjuvant approaches in these patients. Some
cases have already been reported [8,25].
In one case report even interventional arterial
embolization after surgery was effective [18]. Tepetes
et al. reported a case in which adjuvant chemotherapy
and radiofrequency ablation were successful, although
in this case the test for cKit was negative [17]. Two
studies concerning the adjuvant and neoadjuvant
effects of imatinib are being conducted at present,
unfortunately the results are pending at the time of
writing [26,27]. Keeping in mind the high rate of
recurrent disease even after R0 resection [6,14,15],
these studies are very important. (see also Table II).
Debulking operations have not shown significant
survival benefit yet [6,15,25], but this could change
if a neoadjuvant/adjuvant treatment would allow a R0
resection.
Liver resection itself has been shown to prolong
survival; this seems especially true for patients with
small metastasis and a long disease-free interval. A
time to metastasis of /2 years has actually been an
independent predictor of outcome in a large group of
patients published by DeMatteo et al. [15], with a
median survival of 61 months.
Conclusion
Liver resection still provides the only possible cure for
metastatic disease of sarcoma. Extensive resections
using the whole arsenal of modern tools are justified,
as only an R0 resection provides the chance for long-
term survival. GISTs are likely to account for the
largest group of metastases discovered; therefore
preoperative staging including immunohistochemical
examination of acquired specimens is necessary
whenever possible. There are not enough data to
support neoadjuvant/adjuvant treatment in metastatic
disease, but the high recurrence rate after surgery is
evident. Nevertheless, the promising data for primary
GISTs under imatinib therapy suggest the possibility
for preoperative down-staging and improved overall
survival.
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